1
|
Østrem RG, Parhamifar L, Pourhassan H, Clergeaud G, Nielsen OL, Kjær A, Hansen AE, Andresen TL. Secretory phospholipase A 2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo. J Control Release 2017; 262:212-221. [PMID: 28754610 DOI: 10.1016/j.jconrel.2017.07.031] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Revised: 06/30/2017] [Accepted: 07/24/2017] [Indexed: 01/22/2023]
Abstract
The clinical use of liposomal drug delivery vehicles is often hindered by insufficient drug release. Here we present the rational design of liposomes optimized for secretory phospholipase A2 (sPLA2) triggered drug release, and test their utility in vitro and in vivo. We hypothesized that by adjusting the level of cholesterol in anionic, unsaturated liposomes we could tune the enzyme specificity based on membrane fluidity, thus obtaining liposomes with an improved therapeutic outcome and reduced side effects. Cholesterol is generally important as a component in the membranes of liposome drug delivery systems due to its stabilizing effects in vivo. The incorporation of cholesterol in sPLA2 sensitive liposomes has not previously been possible due to reduced sPLA2 activity. However, in the present work we solved this challenge by optimizing membrane fluidity. In vitro release studies revealed enzyme specific drug release. Treatment of two different cancer cell lines with liposomal oxaliplatin revealed efficient growth inhibition compared to that of clinically used stealth liposomes. The in vivo therapeutic effect was evaluated in nude NMRI mice using the sPLA2 secreting mammary carcinoma cell line MT-3. Three days after first treatment all mice having received the novel sPLA2 sensitive liposome formulation were euthanized due to severe systemic toxicity. Thus the present study demonstrates that great caution should be implemented when utilizing sPLA2 sensitive liposomes and that the real utility can only be disclosed in vivo. The present studies have clinical implications, as sPLA2 sensitive formulations are currently undergoing clinical trials (LiPlaCis®).
Collapse
Affiliation(s)
- Ragnhild Garborg Østrem
- Technical University of Denmark, Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Produktionstorvet, 2800 Kgs. Lyngby, Denmark
| | - Ladan Parhamifar
- Technical University of Denmark, Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Produktionstorvet, 2800 Kgs. Lyngby, Denmark
| | - Houman Pourhassan
- Technical University of Denmark, Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Produktionstorvet, 2800 Kgs. Lyngby, Denmark
| | - Gael Clergeaud
- Technical University of Denmark, Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Produktionstorvet, 2800 Kgs. Lyngby, Denmark
| | - Ole Lerberg Nielsen
- Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Ridebanevej 3, 1870 Frederiksberg C, Denmark
| | - Andreas Kjær
- Cluster for Molecular Imaging, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark
| | - Anders Elias Hansen
- Technical University of Denmark, Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Produktionstorvet, 2800 Kgs. Lyngby, Denmark; Cluster for Molecular Imaging, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark
| | - Thomas Lars Andresen
- Technical University of Denmark, Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Produktionstorvet, 2800 Kgs. Lyngby, Denmark.
| |
Collapse
|
2
|
Alberghina M. Phospholipase A2: New lessons from endothelial cells. Microvasc Res 2010; 80:280-5. [DOI: 10.1016/j.mvr.2010.03.013] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2010] [Revised: 03/24/2010] [Accepted: 03/24/2010] [Indexed: 01/05/2023]
|
3
|
Xu C, Ma D, Yu H, Li Z, Liang J, Lin G, Zhang Y, Lai R. A bactericidal homodimeric phospholipases A2 from Bungarus fasciatus venom. Peptides 2007; 28:969-73. [PMID: 17383773 DOI: 10.1016/j.peptides.2007.02.008] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2006] [Revised: 02/09/2007] [Accepted: 02/09/2007] [Indexed: 10/23/2022]
Abstract
Group IIA secretory phospholipases A(2) (sPLA(2)-II) is generally known to display potent gram-positive bactericidal activity, while group IA sPLA(2) (sPLA(2)-I) reportedly is not. In this work, a novel sPLA(2)-I named BFPA was identified from Bungarus fasciatus venom, and its antimicrobial activity was studied as well. The amino acid sequence of the venomous protein precursor was 145-amino acid in length, and contained a predicted 27-amino acid signal peptide and a 118-amino acid mature protein. Unlike the well-known sPLA(2)-Is, which have 14 half-cysteines forming 7 intramolecular disulfide bridges, BFPA possesses 15 half-cysteines. The additional cysteine might contribute to the formation of an intermolecular disulfide bridge of the homodimeric protein. In the biological activities assays, BFPA displayed the activities of anticoagulation and bactericidal against Escherichia coli and Staphylococcus aureus. This study is the first report about gram-positive bactericidal activity of sPLA(2)-I.
Collapse
Affiliation(s)
- Chunhua Xu
- Key Laboratory of Microbiological Engineering of Agricultural Environment, Ministry of Agriculture, Life Sciences College of Nanjing Agricultural University, Nanjing 210095, Jiangsu, China
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Jensen SS, Andresen TL, Davidsen J, Høyrup P, Shnyder SD, Bibby MC, Gill JH, Jørgensen K. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther 2004. [DOI: 10.1158/1535-7163.1451.3.11] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The use of many common clinically relevant chemotherapeutics is often limited due to insufficient delivery to the tumor and dose-limiting systemic toxicities. Therefore, therapeutics that specifically target tumor cells and are nontoxic to normal cells are required. Here, we report the development of a novel class of liposomes composed of lipid prodrugs, which use the increased secretory phospholipase A2 type IIA (sPLA2) activity of the tumor microenvironment as a trigger for the release of anticancer etherlipids (AEL). Treatment of sPLA2-secreting tumor cells in vitro with liposomes consisting of proAELs resulted in growth inhibition comparable with addition of the AELs alone. Using a specific sPLA2 inhibitor, we showed the low cytotoxicity of the nonhydrolyzed proAEL liposomes and have proven the sPLA2 dependency of the activation of proAELs to cytotoxic AELs. In addition, we showed that our proAEL liposomes circumvent the inherent hemolytic toxicities associated with the use of etherlipids, thereby allowing i.v. administration of such therapeutics as nontoxic prodrug liposomes. Furthermore, using a sPLA2-secreting human colon cancer xenograft model, we showed that the proAEL liposomes are capable of inducing a tumor growth delay in vivo. Taken together, these data support the validity of this novel tumor-selective liposomal prodrug delivery strategy. This new approach also provides a promising system for tumor-selective delivery and release of conventional chemotherapeutics encapsulated in the sPLA2-degradable prodrug liposomes.
Collapse
Affiliation(s)
| | - Thomas L. Andresen
- 1LiPlasome Pharma A/S and
- 2Department of Chemistry, Technical University of Denmark, Lyngby, Denmark and
| | | | | | - Steven D. Shnyder
- 3Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Bradford, United Kingdom
| | - Michael C. Bibby
- 3Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Bradford, United Kingdom
| | - Jason H. Gill
- 3Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Bradford, United Kingdom
| | | |
Collapse
|
5
|
Yedgar S, Krimsky M, Schwob O. Protection of cell membrane from exogenous PLA2 and related inflammatory stimuli by membrane-anchored lipid conjugates. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2003; 525:97-101. [PMID: 12751744 DOI: 10.1007/978-1-4419-9194-2_19] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Affiliation(s)
- Saul Yedgar
- Department of Biochemistry, Hebrew University-Hadassah Medical School, Jerusalem, Israel
| | | | | |
Collapse
|
6
|
Abstract
Phospholipase A(2) (PLA(2)) enzymes are involved in lipid metabolism and, as such, are central to several cellular processes. The different PLA(2)s identified to date can be classified into three groups: secreted PLA(2) (sPLA(2)), calcium-independent PLA(2) (iPLA(2)) and calcium-dependent cytosolic PLA(2) (cPLA(2)). In addition to their role in cellular signalling, PLA(2)s have been implicated in diverse pathological conditions, including inflammation, tissue repair and cancer. Elevated levels of sPLA(2) and cPLA(2) have been reported in several tumour types. Here, we summarize the current views on the PLA(2)s, and look at their expression, role in human malignancy and potential as targets for anticancer drug development.
Collapse
Affiliation(s)
- Jonathan P Laye
- Cancer Research UK Laboratories, Tom Connors Cancer Research Centre, University of Bradford, West Yorkshire BD7 1DP, UK
| | | |
Collapse
|